A Greater Manchester patient has become the first in Europe to take part in a complex myositis research study – thanks to close partnership working through the National Institute for Health and Care Research (NIHR) Clinical Research Facility (CRF): Manchester.
Colleagues at the NIHR Manchester CRF sites at Salford Royal and Manchester Royal Infirmary (MRI) worked together to develop a safe and consistent shared care approach for the Chimeric Antigen Receptor (CAR) T-cell trial.
The study required the CRF at Salford Royal1 to identify, recruit and consent patients, the haematology oncology research team at MRI2 to provide specialist CAR T-cell treatment, and CRF colleagues at the MRI to support disease area specific patient assessments during inpatient stay. The patient then returned to Salford for ongoing follow-up.
As well as recruiting the patient to the study, the teams produced practical local guidance on the key steps required to establish advanced therapy clinical trials, where different elements of the patient pathway are delivered across separate NHS organisations, supported by the Advanced Therapy Treatment Centre (ATTC) Network through Innovate Manchester Advanced Therapy Centre Hub (iMATCH). They also created an overall process map, and additional template documentation to support future set up, which has already been used to set up further advanced therapy trials elsewhere in the UK.
At Salford, this work was delivered by principal investigator Prof Hector Chinoy, musculoskeletal research delivery team lead Kathryn Slevin and study coordinator research practitioner Michelle Beswick.
- A poster on the work was presented at the UK and Ireland Clinical Research Facility (CRF) Network conference in Dublin in July.
1 Salford Royal is part of Northern Care Alliance NHS Foundation Trust
2 Manchester Royal Infirmary is part of Manchester University NHS Foundation Trust

